PL3694846T3 - Pochodne 1-benzylo-2-imino-4-fenylo-5-oksoimidazolidyny jako inhibitory proteazy hiv - Google Patents

Pochodne 1-benzylo-2-imino-4-fenylo-5-oksoimidazolidyny jako inhibitory proteazy hiv

Info

Publication number
PL3694846T3
PL3694846T3 PL18796285.7T PL18796285T PL3694846T3 PL 3694846 T3 PL3694846 T3 PL 3694846T3 PL 18796285 T PL18796285 T PL 18796285T PL 3694846 T3 PL3694846 T3 PL 3694846T3
Authority
PL
Poland
Prior art keywords
imino
benzyl
phenyl
protease inhibitors
hiv protease
Prior art date
Application number
PL18796285.7T
Other languages
English (en)
Inventor
Zhenhong R. Cai
Aesop Cho
Ana Zurisadai GONZALEZ BUENROSTRO
Xiaochun Han
Salman Y. Jabri
Ryan Mcfadden
Yingmei Qi
Johannes Voigt
Hong Yang
Jie Xu
Lianhong Xu
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of PL3694846T3 publication Critical patent/PL3694846T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D247/00—Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups C07D229/00 - C07D245/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
PL18796285.7T 2017-10-13 2018-10-12 Pochodne 1-benzylo-2-imino-4-fenylo-5-oksoimidazolidyny jako inhibitory proteazy hiv PL3694846T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572243P 2017-10-13 2017-10-13
PCT/US2018/055554 WO2019075291A1 (en) 2017-10-13 2018-10-12 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS INHIBITORS OF HIV PROTEASE

Publications (1)

Publication Number Publication Date
PL3694846T3 true PL3694846T3 (pl) 2024-08-26

Family

ID=64051787

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18796285.7T PL3694846T3 (pl) 2017-10-13 2018-10-12 Pochodne 1-benzylo-2-imino-4-fenylo-5-oksoimidazolidyny jako inhibitory proteazy hiv

Country Status (23)

Country Link
US (2) US10774053B2 (pl)
EP (1) EP3694846B1 (pl)
JP (2) JP7136892B2 (pl)
KR (1) KR102515284B1 (pl)
CN (1) CN111212832B (pl)
AR (1) AR113765A1 (pl)
AU (1) AU2018347541C1 (pl)
BR (1) BR102018071016A2 (pl)
CA (1) CA3076761C (pl)
CL (1) CL2020000886A1 (pl)
CO (1) CO2020004301A2 (pl)
CR (1) CR20200149A (pl)
EA (1) EA202090530A1 (pl)
ES (1) ES2979368T3 (pl)
IL (1) IL273842A (pl)
JO (1) JOP20180092A1 (pl)
MX (1) MX2020003430A (pl)
PE (1) PE20201497A1 (pl)
PH (1) PH12020550256A1 (pl)
PL (1) PL3694846T3 (pl)
SG (1) SG11202002235XA (pl)
TW (2) TWI697491B (pl)
WO (1) WO2019075291A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021388B1 (pt) 2017-04-11 2023-10-31 Mitsui Chemicals Crop & Life Solutions, Inc Compostos, agente de controle de pragas agrícolas e hortícolas, fungicida agrícola e hortícola e métodos para prevenção e/ou tratamento de uma doença de plantas
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
TW202104210A (zh) * 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
US20200347036A1 (en) * 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
PL4244396T3 (pl) 2020-11-11 2025-12-22 Gilead Sciences, Inc. Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
WO2023074936A1 (ko) * 2021-10-27 2023-05-04 주식회사 오토텍바이오 Ubr 박스 도메인 결합 리간드를 이용한 이중기능성 화합물
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
CR20240223A (es) 2021-12-03 2024-07-08 Gilead Sciences Inc Compuestos terapéuticos para la infección por el virus del vih
US12404262B2 (en) 2021-12-03 2025-09-02 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN115260167B (zh) * 2022-08-01 2025-01-21 陕西盘龙药业集团股份有限公司 一种3-四唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
CN116270698A (zh) * 2023-03-01 2023-06-23 上海复星医药产业发展有限公司 一种复方固体制剂及制备方法和应用
CN116270699A (zh) * 2023-03-07 2023-06-23 上海复星医药产业发展有限公司 一种三方制剂及制备方法和应用
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
CN121219281A (zh) 2023-05-31 2025-12-26 吉利德科学公司 用于治疗hiv的化合物的固体形式
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184452A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2026076265A1 (en) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Combination therapy comprising bridged tricyclic carbamoylpyridone compounds and p-glycoprotein inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
IL157875A0 (en) 2001-04-10 2004-03-28 Pfizer Pyrazole derivatives for treating hiv
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
EP2335701B1 (en) * 2003-12-15 2012-07-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
WO2007059195A1 (en) 2005-11-14 2007-05-24 University Of Southern California Integrin-binding small molecules
US8486983B2 (en) 2005-12-05 2013-07-16 Merck Sharp & Dohme Corp. Self-emulsifying formulations of CETP inhibitors
NZ568904A (en) 2005-12-30 2011-05-27 Merck Sharp & Dohme 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors
EP1973889B1 (en) 2005-12-30 2016-08-24 Merck Sharp & Dohme Corp. Cetp inhibitors
EP1971595B1 (en) 2005-12-30 2013-10-16 Merck Sharp & Dohme Corp. Cetp inhibitors
WO2007092642A2 (en) 2006-02-09 2007-08-16 Merck & Co., Inc. Polymer formulations of cetp inhibitors
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US20110065916A1 (en) 2007-11-26 2011-03-17 Mark Spyvee Method of making imidazoazepinone compounds
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011133719A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
WO2011139637A1 (en) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Small-molecule modulators of hiv-1 capsid stability and methods thereof
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
PE20151063A1 (es) 2012-12-27 2015-08-03 Japan Tobacco Inc DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH
US9840471B2 (en) 2013-02-19 2017-12-12 Senomyx, Inc. Compounds useful as modulators of TRPM8
WO2014150981A1 (en) 2013-03-15 2014-09-25 Elan Pharmaceuticals, Llc Inhibitors of lrrk2 kinase activity
EP3935944A1 (en) 2013-03-15 2022-01-12 University Of Southern California, USC Stevens Compounds for the treatment of musculoskeletal diseases
WO2017142821A1 (en) * 2016-02-18 2017-08-24 Merck Sharp & Dohme Corp. Compounds for the treatment of malaria
US10696639B2 (en) * 2016-12-06 2020-06-30 Merck Sharp & Dohme Corp. Heterocyclic compounds as HIV protease inhibitors
US20200261421A1 (en) * 2016-12-22 2020-08-20 Merck Sharp & Dohme Corp. Heterocyclic compounds as hiv protease inhibitors
WO2018118829A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heterocyclic compounds as hiv protease inhibitors

Also Published As

Publication number Publication date
KR20200071098A (ko) 2020-06-18
CA3076761A1 (en) 2019-04-18
MX2020003430A (es) 2020-07-29
KR102515284B1 (ko) 2023-03-31
BR102018071016A2 (pt) 2019-05-07
US20210078959A1 (en) 2021-03-18
CO2020004301A2 (es) 2020-05-15
CN111212832A (zh) 2020-05-29
IL273842A (en) 2020-05-31
JOP20180092A1 (ar) 2019-04-13
US11352329B2 (en) 2022-06-07
AU2018347541C1 (en) 2022-01-13
AU2018347541A1 (en) 2020-04-16
EP3694846C0 (en) 2024-05-08
PH12020550256A1 (en) 2021-03-01
AU2018347541B2 (en) 2021-06-17
ES2979368T3 (es) 2024-09-25
CR20200149A (es) 2020-05-22
CN111212832B (zh) 2023-09-15
US10774053B2 (en) 2020-09-15
PE20201497A1 (es) 2020-12-29
CL2020000886A1 (es) 2020-10-09
TW201927766A (zh) 2019-07-16
TW202045490A (zh) 2020-12-16
JP2021178852A (ja) 2021-11-18
EA202090530A1 (ru) 2020-10-06
AR113765A1 (es) 2020-06-10
TWI697491B (zh) 2020-07-01
JP2020536911A (ja) 2020-12-17
US20190210978A1 (en) 2019-07-11
WO2019075291A1 (en) 2019-04-18
SG11202002235XA (en) 2020-04-29
CA3076761C (en) 2024-03-26
JP7136892B2 (ja) 2022-09-13
EP3694846B1 (en) 2024-05-08
EP3694846A1 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
IL273842A (en) 1-Benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as HIV protease inhibitors
IL282103B1 (en) Furinones as ubiquitin-specific protease 1 inhibitors
IL268282B (en) hiv inhibitory compounds
ZA201905811B (en) Novel inhibitors
IL250965A0 (en) Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
IL256265B (en) 3-tetrazolyl-benzene-2,1-disulfonamide derivatives as metallo-beta-lactamase inhibitors
EP3447058A4 (en) NEW WIDE SPECTRUM LACTAMASE INHIBITOR
ZA201701575B (en) Pyrrolidinone derivatives as metap-2 inhibitors
EP3142659A4 (en) Hiv-1 protease inhibitors and uses thereof
IL265138B (en) Dopamine-b-hydroxylase inhibitors that penetrate the blood-brain barrier
GB201612860D0 (en) Inhibitors
EP3116862A4 (en) Piperazine derivatives as hiv protease inhibitors
SG11201701378WA (en) Pyrido-oxazinone derivatives as tnap inhibitors
EP3113780A4 (en) Hiv protease inhibitors
EP3192794A4 (en) Sustained hiv protease inhibitor
IL253322A0 (en) bace1 inhibitors
EP3104705A4 (en) Cathepsin cysteine protease inhibitors
PL3484875T3 (pl) Pochodne pirazoliloaminobenzimidazolu jako inhibitory JAK
GB201715589D0 (en) Protease inhibitors
HK40017687A (en) Dopamine-b-hydroxylase inhibitors
GB201616201D0 (en) Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors
HK1235061A1 (en) Pyrazolyl-substituted pyridone compounds as serine protease inhibitors